Skip to Content

Using Tequila Fructans for Drug Delivery

The fruit compounds used to make tequila could also be used to save your colon.

Researchers at the University of Guadalajara, in Mexico, have discovered that fruit compounds taken from the blue-agave plant used to make tequila can be employed as an effective method of delivering drugs to the colon. This development is important for the treatment of colon diseases because physicians have been struggling to find a drug carrier that can withstand stomach acids and deliver medications to the intestine, where they are metabolized.

The blue-agave plant is an important economic product in Mexico because of its role as the base ingredient in tequila. Now researchers are using this ingredient, a fructan compound, as a method of delivering drugs to the colon.

It has been known for many years that the blue-agave plant contains a polysaccharide known as fructan, a polymer of fructose. The compound is not hydrolyzed in acidic environments, such as the upper digestive tract, and it’s therefore able to reach the intestine fully intact. Other plants, such as the chicory, the Jerusalem artichoke, and the dandelion, also contain fructan, but unlike the blue agave, they are unable to produce the large amount of fructan needed to create an effective drug carrier.

To form a drug carrier, the researchers had to chemically modify the extracted fructans to make them nonsoluble in water. They also had to design microspheres of the compound that could encapsulate the drug. To test their method, the researchers filled the microspheres with ibuprofen and exposed them to hydrochloric acid for an hour.

Their laboratory results, presented at the 233rd national meeting of the American Chemical Society, showed the drug to be undamaged. But the group plans to continue working on the design of the microspheres. Within the next year it will be testing the effectiveness of the release of the compounds under the conditions that prevail in the colon. Then the group will move on to animal trials and even further clinical trials.

Keep Reading

Most Popular

Large language models can do jaw-dropping things. But nobody knows exactly why.

And that's a problem. Figuring it out is one of the biggest scientific puzzles of our time and a crucial step towards controlling more powerful future models.

How scientists traced a mysterious covid case back to six toilets

When wastewater surveillance turns into a hunt for a single infected individual, the ethics get tricky.

The problem with plug-in hybrids? Their drivers.

Plug-in hybrids are often sold as a transition to EVs, but new data from Europe shows we’re still underestimating the emissions they produce.

Google DeepMind’s new generative model makes Super Mario–like games from scratch

Genie learns how to control games by watching hours and hours of video. It could help train next-gen robots too.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.